Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. Carrato A, et al. Among authors: layos l. BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7. BMC Cancer. 2019. PMID: 31159765 Free PMC article. Clinical Trial.
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V. Martinez-Balibrea E, et al. Among authors: layos l. Br J Cancer. 2010 Aug 10;103(4):581-9. doi: 10.1038/sj.bjc.6605776. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628391 Free PMC article. Clinical Trial.
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Fernández-Martos C, et al. Among authors: layos l. JAMA Oncol. 2019 Nov 1;5(11):1566-1573. doi: 10.1001/jamaoncol.2019.2294. JAMA Oncol. 2019. PMID: 31465088 Free PMC article.
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Pesántez D, Ten Hoorn S, Machado I, García-Albéniz X, Rodríguez-Salas N, Heredia-Soto V, Viñal D, Pericay C, García-Carbonero R, Losa F, Alonso V, Vera R, Feliu Batlle J, Gallego J, Salud A, Nogué M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Pesántez D, et al. Among authors: layos l. J Natl Cancer Inst. 2023 Dec 6;115(12):1497-1505. doi: 10.1093/jnci/djad120. J Natl Cancer Inst. 2023. PMID: 37405857 Clinical Trial.
Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.
Carrato A, Pazo-Cid R, Macarulla T, Gallego J, Jiménez-Fonseca P, Rivera F, Cano MT, Rodriguez-Garrote M, Pericay C, Alés I, Layos L, Graña B, Iranzo V, Gallego I, Garcia-Carbonero R, de Mena IR, Guillén-Ponce C, Aranda E. Carrato A, et al. Among authors: layos l. NEJM Evid. 2024 Feb;3(2):EVIDoa2300144. doi: 10.1056/EVIDoa2300144. Epub 2024 Jan 23. NEJM Evid. 2024. PMID: 38320486 Clinical Trial.
Curcumin: A therapeutic strategy for colorectal cancer?
Ruiz de Porras V, Layos L, Martínez-Balibrea E. Ruiz de Porras V, et al. Among authors: layos l. Semin Cancer Biol. 2021 Aug;73:321-330. doi: 10.1016/j.semcancer.2020.09.004. Epub 2020 Sep 14. Semin Cancer Biol. 2021. PMID: 32942023 Review.
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Van Cutsem E, et al. Among authors: layos l. J Clin Oncol. 2020 Sep 20;38(27):3185-3194. doi: 10.1200/JCO.20.00590. Epub 2020 Jul 24. J Clin Oncol. 2020. PMID: 32706635 Free PMC article. Clinical Trial.
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M, Abad A. Martinez-Balibrea E, et al. Among authors: layos l. Mol Cancer Ther. 2015 Aug;14(8):1767-76. doi: 10.1158/1535-7163.MCT-14-0636. Epub 2015 Jul 16. Mol Cancer Ther. 2015. PMID: 26184483 Review.
21 results